You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients
  1. Michael A Morse1,
  2. Amy Hobeika1,
  3. William Gwin1,
  4. Takuya Osada1,
  5. Jonathan Gelles2,
  6. Christel Rushing1,
  7. Donna Niedzwiecki1 and
  8. H Kim Lyerly1
  1. Aff1 grid.189509.c0000000100241216Duke University Medical Center Durham NC USA
  2. Aff2 grid.422340.3Alphavax Durham NC USA

https://doi.org/10.1186/2051-1426-3-S2-P444

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    AVX701 is an alphaviral replicon particle vaccine expressing a modified carcinoembryonic antigen gene (CEA(6D)). We previously reported the preliminary results of a Phase I/II study of AVX701 in metastatic colorectal cancer patients (Morse, J Clin Invest. 2010; 120: 3234–3241). Herein, we now report long-term survival for these patients and compare their T cell and antibody responses with the immune responses in a new cohort of stage III colorectal cancer patients immunized similarly with AVX701.

    Methods

    Twenty-eight (28) heavily pretreated patients with predominantly stage IV colorectal cancer were enrolled to 3 dose levels of AVX701 (highest dose 4 × 108 IU i.m. every 3 weeks for 4 immunizations). Subsequently 6 patients with stage III colorectal cancer who had completed adjuvant chemotherapy were enrolled to the same regimen. Peripheral blood from before and after all immunizations was analyzed for immune responses (IR): anti-CEA antibody by ELISA and CEA-specific T cells by ELISPOT.

    Results

    For the entire metastatic cohort (n=28; 23 deaths), median OS was 16 months, 95% CI (8, 25). In those treated at the highest dose (n=19; 14 deaths), there was a trend for a longer median OS among CEA-specific T cell (ELISPOT) immune responders vs nonresponders (not reached vs 13 mo, Log rank p=0.10). ELISA data were too sparse to study OS in the metastatic patients. The difference between maximum anti-CEA antibody (reciprocal) titer and baseline was significantly higher in the Stage III cohort (Normal Scores Test, 2-sided p=0.01) as was the proportion of patients exhibiting IR by ELISA (100% vs 45.1%; Chi-square p=0.02). In the stage III cohort, mean ELISPOT values were significantly higher (F-test p = 0.003) and the rate of CEA-specific T cell response by ELISPOT tended to be higher (67% and 30%; Exact Pearson Chi-square, p=0.16) than in the stage IV cohort.

    Conclusions

    T cell responses following immunization with AVX701 were associated with a trend for longer survival in patients with predominantly stage IV colorectal cancer. The magnitude of antibody response and rate of T cell response tended to be greater in the stage III than stage IV patients which may reflect a less immunosuppressive milieu in patients without measurable disease. We hypothesize that future combinations with checkpoint blockade may enhance efficacy in more immunosuppressive environments.